Drugs & cosmetics amendment bill 2013 major changes

7,362 views

Published on

Published in: Health & Medicine, Business
0 Comments
4 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
7,362
On SlideShare
0
From Embeds
0
Number of Embeds
7
Actions
Shares
0
Downloads
389
Comments
0
Likes
4
Embeds 0
No embeds

No notes for slide

Drugs & cosmetics amendment bill 2013 major changes

  1. 1. Drugs & Cosmetics Amendment Bill 2013 Major Changes Dr. Bhaswat S. Chakraborty
  2. 2. Regulatory Impact Analysis • Need for the regulatory action? • How the regulatory action will meet that need? • An appropriate baseline (i.e., best assessment of how the world would look in the absence of the proposed action). • Based on reasonably obtainable scientific, technical, and economic information and is it presented in an accurate, clear, complete, and unbiased manner? • Benefits from the regulatory action? • Costs implications?
  3. 3. Current D&C Act: Amended up to 2005 • Chapter I: Introductory – scope, definitions etc. • Chapter II: The Drugs Technical Advisory Board, The Central Drugs Laboratory & The Drugs Consultative Committee • Chapter III: Import of Drugs & Cosmetics • Chapter IV: Manufacture, Sale and Distribution of Drugs and Cosmetics • Chapter IVA: Provisions Relating to Ayurvedic, Siddha & Unani Drugs • Chapter V: Miscellaneous • Schedules including Schedule M (2001) and Schedule Y (2005)
  4. 4. Major Amendments Proposed in 2013 Bill • Insertion of 3 subchapters – Chapter 1A – Constitution of Central Drugs Authority (expanded multi-level authority) – Chapter 1B – Clinical Trials (permission & penalties) – Chapter IIA – Import, Manufacture, Sale, Distribution and Export of Medical Devices
  5. 5. Chapter 1A – Constitution of Central Drugs Authority • 13 member category Authority including Health & Family Welfare and DCGI • 11 member categories are ex officio • Only 1 category of membership (4 experts) will require relevant expertise • Only 1 category of membership (4 officers) of State Licensing Authorities • These two categories will have a tenure of 3 years; can be renominated
  6. 6. Chapter 1A – Constitution of Central Drugs Authority.. • Declaration of conflict of interest by members and nonparticipation in such cases. • Vacancies, defective nominations etc., not to invalidate proceedings. • The appointment, salaries, allowances and pensions payable to the DCGI shall be determined by the Central Government. • Necessary staffing for Central Drugs Authority will be created by the Central Government in consultation with the former. • Powers and functions of Central Drugs Authority have been described
  7. 7. Principal Powers and functions of Central Drugs Authority • (a) issue, renew, suspend or cancel licences or certificates or import, export or manufacture of drugs, cosmetics or medical devices or clinical trials; • (b) recall or direct to recall any drug, cosmetic or medical device; • (c) collect the fees or charges for issue or renewal of licences, certificates, approvals and permissions issued by the Central Licensing Authority; • (d) discharge any other functions as may be assigned to him by the Central Drugs Authority;
  8. 8. Other Responsibilities • DCGI shall have administrative control over the officers and employees of the Central Drugs Authority. • Central Government will grant the Central Drugs Authority sums of money as are required by it. • Accounts and audits will be maintained by the Central Drugs Authority. • The Central Drugs Authority shall issue an annual report every year. • Will have power to make relevant rules and regulations.
  9. 9. Chapter 1B – Clinical Trials • No clinical trial without permission. • (1) No person shall initiate or conduct any clinical trial in respect of a new drug or IND or medical device or device IND or cosmetic or BE study of any drug in human subjects without permission by Central Licensing Authority. • (2) No person shall initiate or conduct any clinical trial without an Ethics Committee approval. • (3) No person shall initiate or conduct any clinical trial before it is registered with the Central Drugs Authority.
  10. 10. Other Stipulations re Clinical Trials • • • • • • • • • • • • • Injury or death, whether caused by the trial shall be decided by the DCGI. Medical treatment and compensation due to injury in clinical trials will be decided by DCGI. The Central Licensing Authority may, in public interest, abbreviate, defer or omit the pre-clinical and clinical data requirements for approval of clinical trials. Registration and composition of Ethics Committees and action against EC in case of its failing to discharge its proper function. Inspection by Drugs Control Officer with or without prior notice into any premises related to clinical trial is to be allowed by the sponsor or trial site authority. Disclosure of name, address, etc., of persons involved in clinical trials & maintenance of records and furnishing of information. Penalty for conducting clinical trials without permission, e.g., 3-5 years imprisonment and/or fine up to ten lakh rupees. Penalty for repeat offence and Penalty for violation of conditions of permission. Penalty for failure to provide compensation and Penalty for contravention of any provision of this chapter. Confiscation of stock of the drug or devise as well as the machineries etc. for conducting clinical trials. Cognizance of offences by authority or victim. Powers of central government to make rules about clinical trials. This Chapter not to apply to Ayurvedic, Homeopathy, Siddha or Unani drugs.

×